In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin v. Lucentis: An Early Test Case For Medicare ACOs

Executive Summary

Medicare costs for covering Genentech's Lucentis for wet age-related macular degeneration will get heightened scrutiny now that a widely anticipated National Institutes of Health trial has confirmed that much-less-expensive treatment with the company's Avastin is as effective. Based on 2008 claims data, Medicare is spending about $500 million more on Lucentis than Avastin for treatment of wet AMD.

You may also be interested in...



Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond

The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover new clinical data on TAVI, declining CABG rates in US hospitals, and results from the CATT study comparing Lucentis and Avastin.

Medicare ACO Plan Could Improve Rx Compliance But Lacks Guidance On Drug Management Policies

Medicare-sanctioned accountable care organizations could significantly improve drug adherence among beneficiaries as a way to prevent more costly medical interventions later, under a widely-anticipated CMS proposal.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel